LY9
T-lymphocyte surface antigen Ly-9
Also known as: CD229, hly9, LY9_HUMAN, mLY9, SLAMF3
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q9HBG7
- Gene
- LY9
- Ensembl
- ENSG00000122224
- Chromosome
- 1
- Canonical length
- 655 aa
- Protein class
- CD markers, Predicted membrane proteins, Predicted secreted proteins
- Subcellular location
- Plasma membrane,Centriolar satellite
- Secretome location
- Secreted - unknown location
OverviewNCBI Gene
LY9 belongs to the SLAM family of immunomodulatory receptors (see SLAMF1; MIM 603492) and interacts with the adaptor molecule SAP (SH2D1A; MIM 300490) (Graham et al., 2006 [PubMed 16365421]).[supplied by OMIM, Mar 2008]
Canonical amino-acid sequenceUniProt
655 residues, UniProt reviewed canonical sequence.
>Q9HBG7|LY9
1 MVAPKSHTDD WAPGPFSSKP QRSQLQIFSS VLQTSLLFLL MGLRASGKDS APTVVSGILG
61 GSVTLPLNIS VDTEIENVIW IGPKNALAFA RPKENVTIMV KSYLGRLDIT KWSYSLCISN
121 LTLNDAGSYK AQINQRNFEV TTEEEFTLFV YEQLQEPQVT MKSVKVSENF SCNITLMCSV
181 KGAEKSVLYS WTPREPHASE SNGGSILTVS RTPCDPDLPY ICTAQNPVSQ RSSLPVHVGQ
241 FCTDPGASRG GTTGETVVGV LGEPVTLPLA LPACRDTEKV VWLFNTSIIS KEREEAATAD
301 PLIKSRDPYK NRVWVSSQDC SLKISQLKIE DAGPYHAYVC SEASSVTSMT HVTLLIYRRL
361 RKPKITWSLR HSEDGICRIS LTCSVEDGGN TVMYTWTPLQ KEAVVSQGES HLNVSWRSSE
421 NHPNLTCTAS NPVSRSSHQF LSENICSGPE RNTKLWIGLF LMVCLLCVGI FSWCIWKRKG
481 RCSVPAFCSS QAEAPADTPE PTAGHTLYSV LSQGYEKLDT PLRPARQQPT PTSDSSSDSN
541 LTTEEDEDRP EVHKPISGRY EVFDQVTQEG AGHDPAPEGQ ADYDPVTPYV TEVESVVGEN
601 TMYAQVFNLQ GKTPVSQKEE SSATIYCSIR KPQVVPPPQQ NDLEIPESPT YENFTLocalizationUniProt · AlphaFold · HPA
Whether an antibody against LY9 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.48
- Highest tissue expression
- 29 nTPM
Expression across tissuesHPA
Tissue
- tonsil: 29 nTPM
- lymph node: 28 nTPM
- spleen: 26 nTPM
- thymus: 24 nTPM
- appendix: 13 nTPM
- small intestine: 11 nTPM
Single-cell type
- b-cells: 425 nCPM
- plasma cells: 124 nCPM
- pdcs: 103 nCPM
- t-cells: 74 nCPM
- nk-cells: 53 nCPM
- cdc: 48 nCPM
Immune cell
- MAIT T-cell: 114 nTPM
- gdT-cell: 113 nTPM
- naive CD8 T-cell: 113 nTPM
- naive CD4 T-cell: 110 nTPM
- memory CD8 T-cell: 110 nTPM
- memory CD4 T-cell: 98 nTPM
Brain region
- medulla oblongata: 0.4 nTPM
- spinal cord: 0.4 nTPM
- basal ganglia: 0.3 nTPM
- cerebral cortex: 0.3 nTPM
- choroid plexus: 0.3 nTPM
- pons: 0.3 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.11
- gnomAD pLI
- 0
- gnomAD missense Z
- -0.22
- DepMap mean gene effect
- -0.1
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- cell adhesion
- immune response
- innate immune response
- positive regulation of interleukin-17 production
- T cell activation
- T-helper 17 cell lineage commitment
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of LY9 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads LY9 as an antibody target. Whether an autoantibody or antibody against LY9 could matter depends on whether native LY9 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
LY9 is annotated at the cell surface, where native LY9 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label LY9 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...